ESMO 2022 Conference Coverage


 

ESMO 2022 on the Phase III JIPANG Study: Final OS Analysis of Pemetrexed/Cisplatin vs. Vinorelbine/Cisplatin for Completely Resected Non-Squamous NSCLC

159 views
October 11, 2022
Comments 0
Login to view comments. Click here to Login